A pharmacokinetic drug-drug interaction study between selexipag and midazolam, a CYP3A4 substrate, in healthy male subjects.

Purpose: In vitro data showed that selexipag and its active metabolite (ACT-333679) have an inductive effect on CYP3A4, CYP2B6, and CYP2C9 at concentrations approximately 100-fold higher than the maximum plasma concentration ( C ) measured under steady-state conditions. In order to confirm in vivo t...

Full description

Bibliographic Details

Published in:	European Journal of Clinical Pharmacology Vol. 73; no. 9; pp. 1121 - 1129
Main Authors:	Juif, Pierre-Eric, Boehler, Margaux, Donazzolo, Yves, Bruderer, Shirin, Dingemanse, Jasper
Format:	research tables/charts randomized controlled trial Journal Article
Published:	Springer Nature Sep2017
Online Access:	View this record in EBSCOhost